Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases
BackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases base...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1039614/full |
| _version_ | 1798046022701678592 |
|---|---|
| author | Chunxian Cai Anhua Xiao Xiaoqing Luo Enze Zheng Yiyu Li Yu Lei Shan Zhong Yaxi Chen Ping Yang Zhurong Tang Zhi Zhou |
| author_facet | Chunxian Cai Anhua Xiao Xiaoqing Luo Enze Zheng Yiyu Li Yu Lei Shan Zhong Yaxi Chen Ping Yang Zhurong Tang Zhi Zhou |
| author_sort | Chunxian Cai |
| collection | DOAJ |
| description | BackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases based on the clinic collected data.MethodsA total of 282 subjects were divided into healthy controls (HC, n = 47), chronic hepatitis B (CHB, n = 68), HBV-related liver cirrhosis (HBV-LC, n = 167). Soluble CD36 in plasma was measured by ELISA, and monocyte or platelet CD36 expression was determined by flow cytometry.ResultsThere was a step-wise increase of sCD36 with the progression of chronic HBV infection, and it was the highest in the HBV- LC group with liver failure (1.50, IQR:1.04–2.00) as compared with HC (0.38, IQR:0.27–0.38), CHB (0.75, IQR:0.40–1.13), and HBV-LC without liver failure (1.02, IQR,0.61–1.35) group. Circulating sCD36 was not correlated with serum HBV DNA levels, but correlated with liver function parameters. Additionally, ROC analysis confirmed sCD36 could be used to predict liver failure for HBV-LC patients, which yielded an AUC of 0.775 with 71.0% sensitivity and 72.2% specificity. Multivariate logistic regression analysis revealed sCD36 is an independent risk factor in predicting liver failure. Moreover, plasma sCD36 in HBV-LC patients was significantly correlated with prognostic indices, including MELD, MELD-Na and CHILD-PUGH scores. On the other hand, CD36 expression on monocytes or platelets was positively correlated with plasma sCD36 levels, whereas they were not strongly associated with the disease severity.ConclusionCirculating sCD36 could be used as a novel noninvasive biomarker for predicting liver failure and prognosis in chronic HBV infected patients. |
| first_indexed | 2024-04-11T23:30:46Z |
| format | Article |
| id | doaj.art-07cf7ab3711142908fb53a2e1b40f4a4 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-11T23:30:46Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-07cf7ab3711142908fb53a2e1b40f4a42022-12-22T03:57:07ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2022-11-011310.3389/fmicb.2022.10396141039614Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseasesChunxian Cai0Anhua Xiao1Xiaoqing Luo2Enze Zheng3Yiyu Li4Yu Lei5Shan Zhong6Yaxi Chen7Ping Yang8Zhurong Tang9Zhi Zhou10Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, ChinaInstitute of Life Sciences, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaBackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases based on the clinic collected data.MethodsA total of 282 subjects were divided into healthy controls (HC, n = 47), chronic hepatitis B (CHB, n = 68), HBV-related liver cirrhosis (HBV-LC, n = 167). Soluble CD36 in plasma was measured by ELISA, and monocyte or platelet CD36 expression was determined by flow cytometry.ResultsThere was a step-wise increase of sCD36 with the progression of chronic HBV infection, and it was the highest in the HBV- LC group with liver failure (1.50, IQR:1.04–2.00) as compared with HC (0.38, IQR:0.27–0.38), CHB (0.75, IQR:0.40–1.13), and HBV-LC without liver failure (1.02, IQR,0.61–1.35) group. Circulating sCD36 was not correlated with serum HBV DNA levels, but correlated with liver function parameters. Additionally, ROC analysis confirmed sCD36 could be used to predict liver failure for HBV-LC patients, which yielded an AUC of 0.775 with 71.0% sensitivity and 72.2% specificity. Multivariate logistic regression analysis revealed sCD36 is an independent risk factor in predicting liver failure. Moreover, plasma sCD36 in HBV-LC patients was significantly correlated with prognostic indices, including MELD, MELD-Na and CHILD-PUGH scores. On the other hand, CD36 expression on monocytes or platelets was positively correlated with plasma sCD36 levels, whereas they were not strongly associated with the disease severity.ConclusionCirculating sCD36 could be used as a novel noninvasive biomarker for predicting liver failure and prognosis in chronic HBV infected patients.https://www.frontiersin.org/articles/10.3389/fmicb.2022.1039614/fullsCD36biomarkerHBV-related liver diseasescirrhosisliver failure |
| spellingShingle | Chunxian Cai Anhua Xiao Xiaoqing Luo Enze Zheng Yiyu Li Yu Lei Shan Zhong Yaxi Chen Ping Yang Zhurong Tang Zhi Zhou Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases Frontiers in Microbiology sCD36 biomarker HBV-related liver diseases cirrhosis liver failure |
| title | Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases |
| title_full | Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases |
| title_fullStr | Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases |
| title_full_unstemmed | Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases |
| title_short | Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases |
| title_sort | circulating soluble cd36 as a novel biomarker for progression and prognosis of hbv related liver diseases |
| topic | sCD36 biomarker HBV-related liver diseases cirrhosis liver failure |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1039614/full |
| work_keys_str_mv | AT chunxiancai circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT anhuaxiao circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT xiaoqingluo circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT enzezheng circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT yiyuli circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT yulei circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT shanzhong circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT yaxichen circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT pingyang circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT zhurongtang circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases AT zhizhou circulatingsolublecd36asanovelbiomarkerforprogressionandprognosisofhbvrelatedliverdiseases |